Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.

Two new drugs with mucin-inducing and secretion-promotive effects, rebamipide and diquafosol, were recently approved as topical dry-eye treatments. We report two cases in which the long-term use of mucin-inducing eye drops improved chronic ocular graft-versus-host disease (cGVHD)-related dry eye and ocular cicatricial pemphigoid (OCP)-like disease.
Case 1. A 61-year-old woman had cGVHD-related dry eye that resisted traditional medications. Next, we use topical diquafosol in addition to conventional treatments. The patient used diquafosol for 6 months without experiencing any side effects. The symptoms, including dry-eye sensation, ocular pain, foreign body sensation, and photophobia, as well as ocular surface findings including fluorescein and rose bengal scores and tear break-up time (TBUT), partly improved. To further improve the clinical signs and symptoms and decrease chronic inflammation, rebamipide was added to diquafosol. The symptoms, TBUT, and fluorescein and rose bengal scores markedly improved after long-term dual treatment without any side effects for 6 months. Case 2. A 77-year-old woman had OCP-like disease with dry eye. The patient did not improve using the currently available conventional treatments. Next, we use topical rebamipide in addition to conventional treatments. Symptoms including asthenopia, dry-eye sensation, ocular pain, and dull sensation, as well as fluorescein and rose bengal scores and TBUT, partly improved. Specifically, functional visual acuity was markedly improved after commencement of rebamipide. To further improve the clinical signs and symptoms and increase tear film stability and tear film volume, diquafosol was added to rebamipide. The combination of diquafosol and rebamipide worked for the patient. Improvements were seen in several symptoms, fluorescein and rose bengal scores, Schirmer test value, and TBUT without any side effects for 12 months.
Long-term treatment with topical rebamipide and diquafosol can improve dry eye in patients with cGVHD or OCP-like disease.
AuthorsMio Yamane, Yoko Ogawa, Masaki Fukui, Mizuka Kamoi, Yumiko Saijo-Ban, Saori Yaguchi, Shin Mukai, Tetsuya Kawakita, Shigeto Simmura, Kazuo Tsubota
JournalOptometry and vision science : official publication of the American Academy of Optometry (Optom Vis Sci) Vol. 92 Issue 4 Suppl 1 Pg. S25-32 (Apr 2015) ISSN: 1538-9235 [Electronic] United States
PMID25785527 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • Fluorescent Dyes
  • Ophthalmic Solutions
  • Polyphosphates
  • Purinergic P2Y Receptor Agonists
  • Quinolones
  • Uracil Nucleotides
  • rebamipide
  • diquafosol
  • Alanine
  • Fluorescein
  • Administration, Topical
  • Aged
  • Alanine (analogs & derivatives, therapeutic use)
  • Drug Therapy, Combination
  • Dry Eye Syndromes (diagnosis, drug therapy, etiology)
  • Enzyme Inhibitors (therapeutic use)
  • Female
  • Fluorescein
  • Fluorescent Dyes
  • Follow-Up Studies
  • Graft vs Host Disease (complications, drug therapy)
  • Humans
  • Middle Aged
  • Ophthalmic Solutions
  • Pemphigoid, Benign Mucous Membrane (complications, drug therapy)
  • Polyphosphates (therapeutic use)
  • Purinergic P2Y Receptor Agonists (therapeutic use)
  • Quinolones (therapeutic use)
  • Treatment Outcome
  • Uracil Nucleotides (therapeutic use)
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: